Biogen
Biogen Inc. is an American biopharmaceutical enterprise focusing on the discovery, development, and delivery of therapies for neurological conditions. The company conducts operations under a single biopharmaceuticals business segment dedicated to neurodegenerative diseases. Its commercial drug portfolio includes therapies for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia, and Alzheimer's disease. Revenue generation is primarily driven by global prescription sales of specialty pharmaceuticals and royalty payments from collaborative agreements. The firm maintains a prominent market-leading position in neurology and clinical neuroscience research. Biogen is headquartered in Cambridge, Massachusetts, United States, and trades on the NASDAQ.
50 of the funds FundTelligence covers report a position in Biogen.
- Legal name
- Biogen Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 50
- Exposure themes
- Multiple, Treatment, Women's Health, Ageing & Longevity, Age-Related Disease, Neurodegeneration
Funds holding Biogen
- Fondsfinans Global Helse — Fondsfinans · 5.74 % (full portfolio disclosed, October 2026)
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 5.3 % (partially disclosed portfolio, September 2026)
- HealthInvest Sustainable Healthcare — HealthInvest · 2.6 % (partially disclosed portfolio, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 2.36 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.46 % (full portfolio disclosed, October 2026)
- JPM Global Healthcare Fund — JPM · 1.4 % (full portfolio disclosed, June 2026)
- Schroder ISF Healthcare Innovation — Schroders · 1.08 % (full portfolio disclosed, June 2026)
- DNB Fund Women's Health — DNB · 1.03 % (full portfolio disclosed, August 2026)
Showing the 8 largest of 50 funds holding it.